Trial Profile
A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Sep 2021 Status changed to discontinued, according to Results published in the Oncologist
- 01 Sep 2021 Results published in the Oncologist
- 04 May 2021 Status changed from active, no longer recruiting to completed.